---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-26-000052"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2026-08-05T11:04:39+00:00"
generated_at: "2026-08-05T11:05:48.187547+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entrada reports Q2 net loss of $42.8M; cash $223M; multiple clinical data readouts ahead

## Summary
- Net loss of $42.8M in Q2 2026, roughly flat vs $43.1M in Q2 2025; collaboration revenue $0.9M.
- Cash, equivalents and marketable securities $223.0M as of June 30, 2026, down from $295.7M at Dec 31, 2025; runway into Q3 2027.
- ELEVATE-44-201 Cohort 1 open-label data expected by year-end 2026; Cohort 2 data in Q1 2027.
- ELEVATE-45-201 Cohort 1 data expected October 2026; Cohort 2 dosing at 10 mg/kg ongoing with data in H1 2027.
- Vertex to report VX-670 Phase 1/2 data in DM1 in H2 2026; Entrada advancing preclinical ocular candidate ENTR-801 for USH2A.

## SEC filing metadata
- accession: 0001689375-26-000052
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2026-08-05T11:04:39+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937526000052/0001689375-26-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937526000052/trda-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-26-000052
- JSON: https://secwatch.observer/filing/0001689375-26-000052.json
- Plain text: https://secwatch.observer/filing/0001689375-26-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.